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Abstract
Approximately 15–30% of all breast cancer tumors are estrogen receptor negative (ER2). Compared with ER-positive (ER+)
disease they have an earlier age at onset and worse prognosis. Despite the vast number of risk variants identified for
numerous cancer types, only seven loci have been unambiguously identified for ER-negative breast cancer. With the aim of
identifying new susceptibility SNPs for this disease we performed a pleiotropic genome-wide association study (GWAS). We
selected 3079 SNPs associated with a human complex trait or disease at genome-wide significance level (P,561028) to
perform a secondary analysis of an ER-negative GWAS from the National Cancer Institute’s Breast and Prostate Cancer
Cohort Consortium (BPC3), including 1998 cases and 2305 controls from prospective studies. We then tested the top ten
associations (i.e. with the lowest P-values) using three additional populations with a total sample size of 3509 ER+ cases,
2543 ER2 cases and 7031 healthy controls. None of the 3079 selected variants in the BPC3 ER-GWAS were significant at the
adjusted threshold. 186 variants were associated with ER2 breast cancer risk at a conventional threshold of P,0.05, with P-
values ranging from 0.049 to 2.361024. None of the variants reached statistical significance in the replication phase. In
conclusion, this study did not identify any novel susceptibility loci for ER-breast cancer using a ‘‘pleiotropic approach’’.
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Introduction
Estrogen receptor-negative (ER2) breast cancer (BC) comprises
15 to 30% of all breast tumours (depending on the population) and
has an earlier age at onset and a worse prognosis compared with
estrogen receptor-positive (ER+) disease. It is more common
among women of African-American origin and it is also the breast
cancer type associated with BRCA1 mutations [1,2]. Genome-wide
association studies (GWAS) have identified thousands of common
human genetic variants associated with risk of hundreds of
quantitative traits and human diseases [3,4]. Only seven suscep-
tibility loci have been specifically identified for ER2 BC [5–7]. In
a GWAS, hundreds of thousands or even millions of polymor-
phisms are interrogated at the same time in a strictly agnostic way,
i.e. ignoring any possible a priori knowledge of the SNPs tested.
This model requires use of a stringent significance threshold
(P,561028) to correct for the numerous statistical tests performed
and to avoid false positive findings. As a consequence, it is possible
that variants with a truly positive but weak association are not
detected and, therefore, not reported. A possible drawback of
GWAS is that strict avoidance of false positives may lead to false
negatives [8]. By running secondary analyses using a reduced
number of SNPs defined by biological knowledge or hypothesis,
the required threshold of significance may be lowered and the
power to detect real associations of modest statistical effect may be
increased.
A genetic mechanism termed pleiotropy, which is defined as one
gene, or in this case allele, having an effect on multiple phenotypes
[9] is an example for the selection of candidate SNPs for such
secondary analysis. There are regions in the human genome,
called Nexus, which have been associated with more than one
distinct cancer type [10]. The most striking examples for cancer
are: the 8q24 region, that harbors multiple loci associated with
breast, colon, prostate, bladder and/or ovarian cancers, the TERT
region, which has been associated with pancreatic, bladder, lung
and prostate cancers, the p16 region on chromosome 9p21, and
6q25, and 11q13 associated, respectively, with non-Hodgkins
lymphoma (NHL) and nasopharyngeal carcinoma and with
bladder, breast and prostate cancer [10]. To the best of our
knowledge a pleiotropic approach to identify novel cancer risk
SNPs has been reported only once [11]. A pleiotropic GWAS
performed to examine gene regions associated with pancreatic
cancer, identified a region (HNF1A) previously associated with
several diseases including Type-2 diabetes [12,13].
We used a similar approach to search for new genetic variants
associated with estrogen receptor negative breast cancer suscep-
tibility. We selected all the SNPs that had been associated with a
human disease trait or phenotype, at genome-wide level
(P,561028) and performed a secondary analysis on data from a
GWAS study of ER2 breast cancer by the National Cancer
Institute’s Breast and Prostate Cancer Cohort Consortium (BPC3)
[7]. We then tested the top associations using three additional
populations with a total sample size of 3509 ER+ cases, 2543 ER2
cases and 7031 healthy controls.
Materials and Methods
Ethic statement
The Mammary Carcinoma Risk Factor Investigation (MARIE)
study was approved by the ethics committees of the University of
Heidelberg and the University of Hamburg. Written informed
consent was obtained from all subjects.
For the BPC3 study written informed consent was obtained
from all subjects and ethical approval was collected from the
relevant institutional review boards from each cohort. The cohorts
are: the European Prospective Investigation into Cancer and
Nutrition (EPIC), the Melbourne Collaborative Cohort Study
(MCCS), the Nurses’ Health Study (NHS), the American Cancer
Society Cancer Prevention Study II (CPS-II), the Prostate, Lung,
Colorectal, Ovarian Cancer Screening Trial (PLCO), and the
Multiethnic Cohort (MEC)
Study populations
We performed the study in two phases: first we analysed data
from the BPC3 ER2 GWAS and second, for replication purposes,
we used genotyping or existing data from selected breast cancer
cases and controls collected by three different studies CPS-II,
MCCS and the MARIE study. Individuals from CPS-II contrib-
uted cases and controls to both the initial GWAS and the
replication phase, but there were no overlaps between sample sets
used in the two phases of this study.
The BPC3 has been described extensively elsewhere [14]. It
consists of cases and controls selected from large cohorts assembled
in Europe, Australia and the United States that have both
biological samples and extensive questionnaire information
collected prospectively. Cases were women who were diagnosed
with invasive BC after enrolment, the diagnosis was confirmed by
tumor registries or by medical records. Controls were considered
eligible if they were free of BC until the follow-up time for the
matched case subject. Case and control subjects were matched for
ethnicity and age and for some cohorts also for additional criteria,
such as country of residence. Laboratory techniques and relevant
QCs for the BPC3 ER2 GWAS are extensively reported
elsewhere [7]. Briefly, genotyping was performed at three centers
(Imperial College London, UK, University of Southern California,
USA, and the NCI Core Genotyping Facility, USA). Subjects from
CPSII, EPIC, MEC, PLCO and PBCS were genotyped using the
Illumina Human 660k-Quad SNP array (Illumina, San Diego,
CA, USA), NHSI/NHSII and part of the PLCO study were
genotyped previously using the Illumina Human 550 SNP array
(Illumina, San Diego, CA, USA) [15]. For this study 1998 ER2
invasive cancer cases and 2305 controls belonging to the BPC3
cohort were used.
The MARIE study population comprises BC patients who
participated in a population-based case-control study conducted in
two study regions in Germany (Hamburg and Rhine-Neckar-
Karlsruhe). Cases were women diagnosed with histologically
confirmed primary invasive or in situ breast tumor, aged 50 to
74 years, and residents of the study regions. Detailed information
on tumor hormone receptor status was collected using clinical and
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pathology records. Controls were randomly selected from popu-
lation registries and frequency-matched by year of birth and study
region. The study has been described in more detail elsewhere
[16]. For the present analyses, 2027 cases (370 ER2/1657 ER+)
and 1778 controls were included.
SNPs selection (phase one) and genotyping
The selection of the SNPs to be measured in phase one was
done using the National Human Genome Research Institute’s
(NHGRI’s) catalog of published GWA studies (http://www.
genome.gov/gwastudies/) [4]. It contains summary information
on polymorphic variants reported to be associated with a human
disease, trait or phenotype in a GWA setting at the significance
level of P,1.061025. The data from the catalogue were
downloaded in May 2012 and comprised 7986 SNPs. Approxi-
mately 60% (n= 5794) of the polymorphic variants reported in the
catalogue had a P value higher than 561028 and were, therefore,
excluded from further analysis. Of the remaining 3192 SNPs, 1688
(58%) were genotyped in the BPC3 scan. PLINK [17] was used to
identify highly correlated (r2.0.9 in Hapmap3 CEU) SNPs
genotyped in the BPC3 GWAS for 452 variants (14.2% of the total
selected SNPs). Data for 939 SNPs were imputed: 901 (28.3% of
the total selected SNPs) from Hapmap 2 and 38 (1.1% of the total
selected SNPs) from Hapmap3. The remaining 113 (3.6% of the
total selected SNPs) variants were dropped from the analysis since
no surrogate was found and it was not possible to impute data.
Thus, data for 3079 out of 3192 catalogued SNPs (96.4%) were
used for this study.
The 3079 remaining SNPs were looked up in the BPC3 GWAS
ranking the P-value in decreasing order to check for their
association. All already known breast cancer risk SNPs were
excluded from the analysis.
Replication (phase two) genotyping
In order to confirm the ten most significant findings we used
additional BC cases and controls from three studies of women of
Caucasian descent as a replication set: the CPS-II [18] consisting
of 1530 estrogen receptor positive (ER+) cases, 53 ER2 cases and
2395 healthy controls, the MCCS [19] with 322 ER+ cases, 122
ER2 cases and 823 healthy controls, and the MAmmary
carcinoma Risk factor InvEstigation (MARIE) [16] with 1657
ER+ cases, 370 ER2 cases and 1778 healthy controls, for a total
of 3684 cases and 4996 controls. Specifically rs498872, rs2000999,
rs12150660, rs780094, rs11229030 and rs13397985 were repli-
cated in silico for the MARIE, CPSII and MCCS studies. These six
SNPs were genotyped as part of the iCOGS study using a custom
Illumina array. In the original iCOGS publications SNPs with
MAF ,1%; call rate ,95%; or call rate ,99% and MAF ,5%
and all SNPs with genotype frequencies that departed from
Hardy-Weinberg equilibrium at P,161026 for controls or
P,1610212 for cases were excluded [5,20]. The remaining four
SNPs rs8396, rs4788815, rs2571391, rs780092 were not present in
the iCOGS array and were, therefore, genotyped de novo for the
MARIE study by TaqMan. The mean genotyping success rate was
94.4% (88.2%–96.7%). The percentage of samples that was
genotyped twice for quality assurance was 9.5%, the genotyping
concordance was 99.99%. Departure from Hardy Weinberg
equilibrium was tested for the ten SNPs for the respective control
subjects from each study.
Statistical analysis
Logistic regression adjusted for five principal components, age
(at diagnosis for cases and at selection for controls) and cohort was
used to generate ORs, 95% CIs, and P values for each of the 3079
SNPs selected from the BPC3 ER negative GWA data set and for
the 10 SNPs in the replication phase. The replication was
performed using ER2 and ER+ breast cancer cases and the
analysis was conducted using ER2 alone and in combination with
ER+. Considering the fact that several ER2 SNPs are also
associated with ER+ BC we included in the analysis ER+ and
ER2 cases and then analyzed overall BC risk (ER+ and ER2)
and ER2 specific (ER2 alone) to increase our power to find a true
association. We had more than 90% power to replicate any of the
associations observed in the discovery phase if considering all BC
cases, and over 50% (53%–72%) power if considering only ER2
cases considering alpha of 0.05. Using a conservative Bonferroni
correction, we considered a threshold of P-values,1.661025
(0.05/3079) as statistically significant.
Figure 1. Manhattan Plot of all SNPs analyzed in phase one of the study.
doi:10.1371/journal.pone.0085955.g001
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Results
None of the 3079 selected variants in the BPC3 ER-GWAS was
significant at the adjusted threshold. 186 variants were associated
with ER2 breast cancer risk at a conventional threshold of
P,0.05, with P values ranging from 0.049 to 2.361024 (Figure 1).
The strongest observed association was a decreased risk of ER2
BC with rs8396 (ORhetero :0.84; 95% CI 0.76–0.92 and
ORhomo0.71 (CI 95% 0.58–0.85)). We selected the most significant
10 SNPs (shown in table 1) and analyzed them using independent
samples to determine whether they were genuinely associated with
BC overall and for ER2 breast cancer in particular. All the
polymorphic variants were in Hardy-Weinberg equilibrium with
the exception of rs12150660 in the CPSII and MARIE cohorts
and rs13397985 in the CPSII cohort. Therefore, CPSII was not
used as a replication set for rs12150660 and rs13397985 and
MARIE was not used for rs12150660. In addition, one
polymorphic variant rs8396 was not used in the analysis because
it had a call rate lower than 95% (88.2%).
Only rs11229030, a variant originally found associated with risk
of Crohn’s disease, was nominally associated with a decreased risk
of ER2 BC (OR 0.85, CI 95% 0.75–1.00, P value = 0.049). The
association was observed only for the MARIE study. The results of
all the analyses are shown in table 1. Additional information on
the original reports can be found at http://www.genome.gov/
gwastudies/. We also performed meta-analysis between the
various studies but the results were very heterogeneous, clearly
suggesting a negative finding (Forest plots, heterogeneity P-values
and I2 statistics are shown in figure S1).
Discussion
Pleiotropy is a fairly common phenomenon that is defined as
one gene or allelic variant having an effect on multiple phenotypes.
In a recent paper based on data from the catalogue of published
GWAS, Sivakumaran and colleagues have reported that 4.6% of
the SNPs and 16.9% of the genes present in the catalogue are
shown to have pleiotropic effects [9]. These percentages probably
Table 1. The strongest associations between the pleiotropic SNPs and breast cancer risk.
SNP Name study ER status ORa 95% CIb P_trendc study ER status OR 95%CI P_trend
rs2000999 [22] BPC3 ER+/ER2 0.83 (0.75–0.93) 6.72E-04 BPC3 ER2 0.83 (0.75–0.93) 6.72E-04
MCCS ER+/ER2 1.05 (0.85–1.30) 6.30E-01 MCCS ER2 1.14 (0.80–1.62) 4.80E-01
CPS2 ER+/ER2 0.94 (0.85–1.04) 2.41E-01 CPS2 ER2 0.88 (0.53–1.46) 6.19E-01
MARIE ER+/ER2 1.02 (0.91–1.15) 7.26E-01 MARIE ER2 0.99 (0.81–1.20) 8.85E-01
rs12150660 [23] BPC3 ER+/ER2 0.84 (0.76–0.93) 8.58E-04 BPC3 ER2 0.84 (0.76–0.93) 8.58E-04
MCCS ER+/ER2 1.00 (0.82–1.21) 9.70E-01 MCCS ER2 0.79 (0.56–1.11) 1.70E-01
CPS2 ER+/ER2 0.94 (0.84–1.05) 2.74E-01 CPS2 ER2 1.21 (0.74–1.98) 4.53E-01
MARIE ER+/ER2 1.16 (1.04–1.31) 1.07E-02 MARIE ER2 1.18 (0.97–1.42) 9.87E-02
rs13397985 [24] BPC3 ER+/ER2 0.84 (0.76–0.94) 2.18E-03 BPC3 ER2 0.84 (0.76–0.94) 2.18E-03
MCCS ER+/ER2 1.09 (0.88–1.35) 4.20E-01 MCCS ER2 0.95 (0.66–1.38) 8.00E-01
CPS2 ER+/ER2 0.94 (0.82–1.08) 3.58E-01 CPS2 ER2 1.16 (0.65–2.07) 6.17E-01
MARIE ER+/ER2 1.11 (0.98–1.26) 8.65E-02 MARIE ER2 1.16 (0.95–1.42) 1.46E-01
rs780094 [25] BPC3 ER+/ER2 0.87 (0.80–0.94) 9.97E-04 BPC3 ER2 0.87 (0.80–0.94) 9.97E-04
MCCS ER+/ER2 1.01 (0.86–1.19) 8.70E-01 MCCS ER2 0.94 (0.72–1.24) 6.80E-01
CPS2 ER+/ER2 0.96 (0.88–1.04) 3.00E-01 CPS2 ER2 0.98 (0.67–1.45) 9.29E-01
MARIE ER+/ER2 1.02 (0.92–1.12) 7.38E-01 MARIE ER2 0.97 (0.83–1.14) 7.34E-01
rs11229030 [26] BPC3 ER+/ER2 0.87 (0.80–0.95) 1.95E-03 BPC3 ER2 0.87 (0.80–0.95) 1.95E-03
MCCS ER+/ER2 0.98 (0.83–1.15) 8.00E-01 MCCS ER2 1.01 (0.77–1.33) 9.20E-01
CPS2 ER+/ER2 1.02 (0.94–1.11) 6.60E-01 CPS2 ER2 1.31 (0.89–1.94) 1.72E-01
MARIE ER+/ER2 0.98 (0.89–1.08) 6.22E-01 MARIE ER2 0.85 (0.72–1.00) 4.94E-02
rs780092 [27] BPC3 ER+/ER2 1.20 (1.07–1.34) 2.06E-03 BPC3 ER2 1.20 (1.07–1.34) 2.06E-03
MARIE ER+/ER2 1.03 (0.94–1.14) 4.96E-01 MARIE ER2 0.90 (0.74–1.10) 3.17E-01
rs4788815 [28] BPC3 ER+/ER2 0.85 (0.78–0.93) 5.29E-04 BPC3 ER2 0.85 (0.78–0.93) 5.29E-04
MARIE ER+/ER2 0.99 (0.92–1.06) 6.94E-01 MARIE ER2 1.14 (0.99–1.31) 7.50E-02
rs2571391 [29] BPC3 ER+/ER2 1.16 (1.06–1.27) 1.42E-03 BPC3 ER2 1.16 (1.06–1.27) 1.42E-03
MARIE ER+/ER2 1.03 (0.95–1.10) 4.82E-01 MARIE ER2 0.91 (0.79–1.06) 2.25E-01
rs498872 [30] BPC3 ER+/ER2 1.15 (1.05–1.26) 2.21E-03 BPC3 ER2 1.15 (1.05–1.26) 2.21E-03
MCCS ER+/ER2 0.96 (0.80–1.15) 6.60E-01 MCCS ER2 1.05 (0.78–1.43) 7.30E-01
CPS2 ER+/ER2 0.92 (0.85–1.01) 7.10E-02 CPS2 ER2 0.96 (0.63–1.47) 8.50E-01
MARIE ER+/ER2 1.01 (0.91–1.12) 9.07E-01 MARIE ER2 0.96 (0.80–1.14) 6.11E-01
aOR = Odds Ratio.
b95% CI = 95% Confidence Intervals.
cAll analysis were adjusted for age at diagnosis and in the BPC3 for cohort of provenience.
doi:10.1371/journal.pone.0085955.t001
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underestimate the real biological significance, since they have been
obtained using a very conservative threshold, such as considering
only the SNPs available in the catalogue and associated with a
particular disease or trait at a genome wide level. Using data from
GWAS meta-analyses, pleiotropy seems to play a much stronger
role for specific diseases, for example Cotsapas and collaborators
reported that 44% of the susceptibility loci for autoimmune
diseases overlap [21]. In a two-staged analysis of 3509 ER+ cases,
2543 ER2 and 7031 healthy controls, none of the SNPs showed a
statistically significant association with breast cancer in the
replication analysis. The strongest signal, in the replication
analysis, was given by rs11229030 (a Crohn’s disease susceptibility
allele) that was associated with a decreased risk of ER2 BC (P
value = 0.049) only in the MARIE study, but not in CPS-II or
MCCS suggesting that the association found is probably due to
chance.
There are several possible reasons why our pleiotropic approach
failed to identify new SNP associatated with ER2 BC. First, ER2
BC may be associated with uncommon biologic pathways that are
not shared with many other diseases and, therefore, may not be
influenced by pleiotropy. This is consistent with the fact that there
are several SNPs which are specifically associated with ER2 but
not ER+. Alternatively, ER2 BC may share genetic risk factors
with other common disease traits and phenotypes, but not with
those we included in our analysis. The pleiotropic approach we
used is necessarily limited by the number of disease traits and
phenotypes that have been examined with enough statistical power
to identify GWAS hits. It is possible that disease traits and
phenotypes with biologic pathways similar to ER2 BC have not
been examined adequately and are yet to be included in the
NHGRI database.
We are aware of several limitations that this work might present:
first, we were not able to include all the SNPs from the catalogue
because 113 (3.6% of the total selected SNPs) variants were
dropped from the analysis since no surrogate was obtained and it
was not possible to impute data. Second, we replicated, as an
exploratory analysis, only the 10 most significant SNP associations,
thus we cannot exclude that a true positive association lies those
SNPs that we did not attempt to replicate in the second phase,
although due the complete lack of replication of the first ten SNPs
this possibility seems unlikely. Third, we have included only the
SNPs present in the GWAS catalogue, but we did not include
other SNPs present in the regions. Since in pleiotropic regions the
SNPs associated with different traits or diseases are not always the
same, we can not exclude the possibility that we might have left
out SNPs that are truly associated with ER2 but that are not yet
present in the GWAS catalogue. The other limitation is the sample
size of the replication set which is quite large, considering the
rarity of the disease, but might have been inadequate to detect
weaker associations.
In conclusion, and given the limitations summarized, we did not
identify any pleiotropic SNP associated with ER-breast cancer.
Supporting Information
Figure S1 Forest plots, I2 and heterogeneity P-values for
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